Find News

Filter articles

Showing 3101 to 3110 of 3417 results

Sanofi sues Eli Lilly to halt Lantus biosimilar

US10-07-2014Legal developments

French pharmaceutical company Sanofi has sued Eli Lilly for infringing seven patents that cover its blockbuster diabetes drug Lantus (insulin glargine).

Acorda challenges Actavis’s Ampyra generic


US-based Acorda Therapeutics has sued Actavis for infringing four patents covering its multiple sclerosis (MS) drug Ampyra (dalfampridine).

Stites & Harbison welcomes two life sciences partners


Tennessee-based law firm Stites & Harbison PLLC has expanded its IP and technology practice with the hire of life sciences partners Kelly Hollowell and Justin McNaughton.

NeuClone and Serum Institute collaborate on biosimilars

Australia, India08-07-2014

Australian biotechnology company NeuClone has signed an agreement with vaccine maker the Serum Institute of India to manufacture and supply ten biosimilar monoclonal antibody drugs around the world.

Chinese national arrested for conspiring to steal seed trade secrets


An ex-employee for a large Chinese seed production company has been arrested in the US for conspiring to steal trade secrets from US agricultural companies including Monsanto.

MMR Global and Claydata enter into licensing agreement


Personal health records company MMR Global has entered into a licensing agreement with Australian medical database company Claydata.

Aurobindo sued by Pfizer over skin antibiotic


Pfizer has launched a lawsuit against Aurobindo Pharma accusing the Indian pharmaceutical company of infringing patents related to an antibiotic used to treat skin infections.

Actavis completes $1.1bn Furiex acquisition

US03-07-2014Mergers & acquisitions

Actavis’s newly-acquired subsidiary Forest Laboratories has bought drug development company Furiex Pharmaceuticals for $1.1 billion.

Johnson & Johnson IP chief lined up for USPTO role


The head of IP at a major pharmaceutical company is set to be named as the next director of the US Patent and Trademark Office, reports have claimed.

Genentech adds to breast cancer pipeline with Seragon buyout

US02-07-2014Mergers & acquisitions

Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.7 billion.

Showing 3101 to 3110 of 3417 results